Skip to content

Tranexamic Acid and Pediatric Adenotonsillectomy

Use of Tranexamic Acid for Bleeding Reduction in Adenotonsillectomy in Children

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01228136
Enrollment
95
Registered
2010-10-26
Start date
2010-01-31
Completion date
2010-12-31
Last updated
2010-12-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adenoidectomy, Tonsillectomy, Tranexamic Acid

Keywords

Adenotonsillectomy, Tranexamic acid, Blood loss, Postoperative hemorrhage

Brief summary

The purpose of this study is to determine if the use of tranexamic acid prior adenotonsillectomy in children can reduce surgical and postoperative bleeding.

Detailed description

Tonsillectomy with or without adenoidectomy is the most common major surgical procedure performed in children. Although it's a relatively simple procedure, may present complications as hemorrhage and death. The mortality associated to the surgery range between 1/1.000 and 1/27.000 in the literature, with approximately 30% due to hemorrhage. Tranexamic acid is an antifibrinolytic hemostatic indicated to control bleeding in cases of hyperfibrinolysis or defective hemostasis diseases. It's major indications are prostatic surgery and menorrhagia.

Interventions

DRUGTranexamic Acid

10mg/Kg, IV (in the vein), first dose 30 minutes before surgery, second dose 8 hours after first dose, third dose 8 hours after second dose

OTHERnormal saline solution

normal saline solution in the same volume calculated as treatment (tranexamic acid 250mg/mL, 10mg/Kg), IV (in the vein) first dose 30 minutes before surgery, second dose 8 hours after first dose, third dose 8 hours after second dose

Sponsors

Irmandade Santa Casa de Misericórdia de Porto Alegre
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
4 Years to 12 Years
Healthy volunteers
No

Inclusion criteria

* children with 4 to 12 years * adenotonsillar hypertrophy * indication of adenotonsillectomy

Exclusion criteria

* patients with blood dyscrasia * patients with history of bleeding of difficult control or spontaneous hematoma * patients with coagulation tests altered * patients with evidence of hematopoietic, cardiovascular, hepatic, renal, neurologic, psychiatric or auto immune disease

Design outcomes

Primary

MeasureTime frameDescription
volume of intraoperative bleedingone dayintraoperative bleeding (in mL of aspirated blood) measured at the end of the surgical procedure

Secondary

MeasureTime frameDescription
incidence of postoperative bleedingten daysincidence of oral bleeding at the ten days after surgery, evaluated by a patient's diary and postoperative medical evaluations

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026